| Revenue growth | 15.66% YoY for FY26. |
|---|---|
| Margins | EBITDA margin softened to 8.56% in FY26 vs 10.64% in FY25. |
| Demand visibility | Strong volume growth in regulated markets. |
| Management confidence | High, citing strong regulatory compliance and capacity enhancements. |
Growth
FY26 Revenue rose 15.7% to ₹776 Cr; EBITDA grew 6.5% to ₹67.84 Cr; Total Production up 25% to 1733 MT.
Outlook
Capacity expanded to 2400 MTPA; focus on niche APIs, process innovation, and increasing export share in regulated markets.
Risks
Global market challenges impacted Q4 profitability; currency risks mentioned regarding export dependency.
Earnings Call filed with BSE, NSE: ANUHPHR. Summary written with AI assistance from the document.
Anuh Pharma Ltd: key numbers
- Share price
- ₹86.09
- Market cap
- ₹862.8 Cr
- Revenue (annual)
- ₹771.7 Cr
- Net profit (annual)
- ₹41.05 Cr
- P/E (TTM)
- 19.5×Sector 47.4×
- Promoter holding
- 71.80%+0.00% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anuh Pharma Ltd
All →Anuh Pharma Legal & Regulatory
Anuh Pharma disclosed a Rs. 9,93,206 tax demand under Section 156, Income Tax Act, for AY 2018-19. The company plans to appeal before the CIT.
- Value
- ₹0.10 Cr
Anuh Pharma Investor Presentation: Key Takeaways
Anuh Pharma reported strong Q1 FY27 results with 4% YoY revenue growth and 38% PAT growth, driven by a shift to high-value regulated markets.
- Call
- Guides 18% growth
Anuh Pharma Management Change
Anuh Pharma announced the re-appointment of directors Arun Lalchand Todarwal and Bipin N. Shah, and the appointment of Ankit Kishor Chande as Cost Auditor.
Anuh Pharma Annual General Meeting
Anuh Pharma Ltd held its 66th Annual General Meeting on August 12, 2026. The meeting covered the adoption of financial statements, dividend declaration, and director appointments.
Anuh Pharma Other Announcement
Anuh Pharma Ltd. promoters withdrew their application for reclassification from 'Promoter Group' to 'Public' category. They will continue to remain part of the Promoter Group.
Anuh Pharma Q1 FY27 Results: Net Profit ₹11.4 Cr, Up 37.3% YoY
Anuh Pharma Ltd reported revenue from operations of ₹193.8 Cr (+3.9% YoY) and net profit of ₹11.4 Cr (+37.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹11.4 Cr · +37.3% YoY